Skip to content
Kalpvruksh Markets
Offline Log in

SPARCNSEOffline

SUNPHADVPP · IN9232I01012
—last close
Prev close
—
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
—
52-week range · to 05 Nov 2026108.71277.57

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

SPARC is 29% below its 52-week high, above its 200-day average.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · 29% below its 52-week high
  • −8.2% vs Nifty 500
  • traded value 1.4× usual · delivery 39% vs 41% usual
  • FPI −0.2 pp · DII +0.0 pp · MF schemes in Sept 2026: 3 bought, 4 cut · no promoter pledge · quarter ended 2026-09-30
  • nothing scheduled or restricting

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+7.2%+1.3 pts—
1 month−0.4%−4.8 pts—
3 months−10.2%−8.2 pts—
6 months+24.9%+24.4 pts—
1 year+43.2%+47.0 pts—

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+7.3%
above
vs 50-day average
+2.1%
above
vs 200-day average
+9.8%
above
ATR (14)
4.7%
typical daily range
Volatility
45%
1 month, annualised
Beta
1.93
vs Nifty 500, 1 year
Traded value
1.4×
vs usual
Delivery
39%
usual 41%
From the 52-week high
−29.3%
place in range 52% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters65.7%65.7%65.7%65.7%
FPI2.0%2.0%3.9% +1.93.7% −0.2
Mutual funds0.8%0.8% +0.10.1% −0.80.1%
Other DII0.0%0.0%0.0%0.0%
Individuals19.2%16.8% −2.418.6% +1.818.6% +0.1
Others12.3%14.6% +2.311.8% −2.811.8% +0.1

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Jun 25 noneSep 25 noneDec 25 noneMar 26 noneJun 26 noneSep 26 none

Holders

Sep 26

All shareholders
1,41,992
Individuals
1,36,083

Which funds bought and sold

mutual funds · quarter ended

Funds holding
9
9 index · 0 active
Bought more
6
Sold some
2
FundSharesChangeDid
Motilal Oswal Nifty Microcap 250 Index Fund-Reg(G)Index−22,794−8.1%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 2680340+3.3%₹6 cr
Aug 2680410+1.1%₹6 cr
Jul 2681230+11.7%₹6 cr
Jun 2670330−3.2%₹6 cr
May 2670221−86.7%₹6 cr
Apr 2680330−29.2%₹29 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 1 of 1 disclosures
0 selected
19 May 2026Shanghvi Finance Private LimitedPromoter GroupBuy3,85,10,000₹150 cr1.00%Preferential Offer

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2026.
    03 Nov 2026
  • Board outcome
    Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter ended June 30, 2026.
    10 Aug 2026
  • Board outcome
    Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2026.
    10 Aug 2026
  • Bulk deal: SELL
    18,95,932 at ₹240.86 — HRTI PRIVATE LIMITED
    26 May 2026
  • Bulk deal: BUY
    19,86,488 at ₹240.53 — HRTI PRIVATE LIMITED
    26 May 2026
  • Bulk deal: SELL
    23,63,979 at ₹226.35 — HRTI PRIVATE LIMITED
    25 May 2026
  • Bulk deal: BUY
    25,32,120 at ₹226.9 — HRTI PRIVATE LIMITED
    25 May 2026

Latest shown; 8 in six months on all disclosures.

SPARC: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.